Revance Therapeutics is a biotechnology company that develops and manufactures neuromodulators for various aesthetic and therapeutic purposes. Its lead drug candidate, DaxibotulinumtoxinA, has completed phase III clinical trials for the treatment of frown lines and cervical dystonia. The company is also developing the drug for the treatment of other indications and has a collaboration agreement with Viatris to develop, manufacture, and commercialize onabotulinumtoxinA.